| Microcredit: What can we learn from the past? A Hollis, A Sweetman World Development 26 (10), 1875-1891, 1998 | 369 | 1998 |
| World Health Organization (WHO) guidelines on use of medically important antimicrobials in food-producing animals A Aidara-Kane, FJ Angulo, JM Conly, Y Minato, EK Silbergeld, ... Antimicrobial Resistance & Infection Control 7 (1), 7, 2018 | 320 | 2018 |
| Co-authorship and the output of academic economists A Hollis Labour economics 8 (4), 503-530, 2001 | 282 | 2001 |
| Preserving antibiotics, rationally A Hollis, Z Ahmed New England Journal of Medicine 369 (26), 2474-2476, 2013 | 270 | 2013 |
| The Health Impact Fund: Making New Medicines Accessible for All: a Report of Incentives for Global Health A Hollis, TWM Pogge, Incentives for Global Health Incentives for Global Health, 2008 | 224 | 2008 |
| An economic justification for open access to essential medicine patents in developing countries S Flynn, A Hollis, M Palmedo The Journal of Law, Medicine & Ethics 37 (2), 184-208, 2009 | 189 | 2009 |
| Estimating the clinical cost of drug development for orphan versus non-orphan drugs K Jayasundara, A Hollis, M Krahn, M Mamdani, JS Hoch, P Grootendorst Orphanet journal of rare diseases 14 (1), 12, 2019 | 155 | 2019 |
| The importance of being first: evidence from Canadian generic pharmaceuticals A Hollis Health Economics 11 (8), 723-734, 2002 | 133 | 2002 |
| The life-cycle of a microfinance institution: The Irish loan funds A Hollis, A Sweetman Journal of Economic Behavior & Organization 46 (3), 291-311, 2001 | 133 | 2001 |
| Impact of isolation precautions on quality of life: a meta-analysis A Sharma, DR Pillai, M Lu, C Doolan, J Leal, J Kim, A Hollis Journal of Hospital Infection 105 (1), 35-42, 2020 | 121 | 2020 |
| Microcredit in prefamine Ireland A Hollis, A Sweetman Explorations in Economic History 35 (4), 347-380, 1998 | 116 | 1998 |
| Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus CM Morel, O Lindahl, S Harbarth, MEA de Kraker, S Edwards, A Hollis The Journal of antibiotics 73 (7), 421-428, 2020 | 114 | 2020 |
| The Health Impact Fund: incentives for improving access to medicines A Banerjee, A Hollis, T Pogge Lancet (London, England) 12 (9709), 2010 | 110 | 2010 |
| A contractual approach to the gray market NT Gallini, A Hollis International Review of Law and Economics 19 (1), 1-21, 1999 | 110 | 1999 |
| The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers J MacCormack, A Hollis, H Zareipour, W Rosehart Energy policy 38 (7), 3837-3846, 2010 | 103 | 2010 |
| An efficient reward system for pharmaceutical innovation A Hollis Retrieved Dec 9, 2004 | 95 | 2004 |
| The anti-competitive effects of brand-controlled" pseudo-generics" in the Canadian pharmaceutical market A Hollis Canadian Public Policy/Analyse de Politiques, 21-32, 2003 | 94 | 2003 |
| Attitudes, behaviours and barriers to public health measures for COVID-19: a survey to inform public health messaging R Lang, JL Benham, O Atabati, A Hollis, T Tombe, B Shaffer, KK Burns, ... BMC Public Health 21 (1), 765, 2021 | 87 | 2021 |
| Antibiotic resistance is a tragedy of the commons that necessitates global cooperation A Hollis, P Maybarduk Journal of Law, Medicine & Ethics 43 (S3), 33-37, 2015 | 81 | 2015 |
| Knowledge gaps in the understanding of antimicrobial resistance in Canada KD McCubbin, RM Anholt, E de Jong, JA Ida, DB Nóbrega, JP Kastelic, ... Frontiers in public health 9, 726484, 2021 | 77 | 2021 |
Paul GrootendorstProfessor, University of TorontoVerified email at utoronto.ca
